Victory Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Victory Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	-$2.5K	–	2662
2023 Q3	$2.5K	Buy	4 +1	+33%	+$4.29K	﹤0.01%	2514
2023 Q2	$15.5K	Hold	3	–	–	﹤0.01%	2464
2023 Q1	$8.05K	Hold	3	–	–	﹤0.01%	2557
2022 Q4	$7.97K	Hold	3	–	–	﹤0.01%	2553
2022 Q3	$12K	Sell	3 -1	-25%	-$3.93K	﹤0.01%	2650
2022 Q2	$10K	Hold	4	–	–	﹤0.01%	2653
2022 Q1	$8K	Hold	4	–	–	﹤0.01%	2689
2021 Q4	$23K	Hold	4	–	–	﹤0.01%	2688
2021 Q3	$36K	Hold	4	–	–	﹤0.01%	2706
2021 Q2	$41K	Buy	4 +1	+33%	+$16.4K	﹤0.01%	2678
2021 Q1	$54K	Buy	+3	New	+$35K	﹤0.01%	2664
2020 Q2	–	Sell	-4	Closed	-$6K	–	3385
2020 Q1	$6K	Buy	+4	New	+$14.9K	﹤0.01%	3459
2019 Q4	–	Sell	-1	Closed	-$3K	–	3373
2019 Q3	$3K	Buy	+1	New	+$6.03K	﹤0.01%	3587

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Victory Capital Management's SEEL Position: Q4 2023 in Review

Victory Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 4 shares — an estimated $2.5K sold.

Victory Capital Management first reported a position in SEEL in Q3 2019 and held it in 13 quarters. The position peaked at $54K in Q1 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

Victory Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Victory Capital Management sold 4 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.5K.
Victory Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 13 quarters.
Victory Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $54K in Q1 2021.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Victory Capital Management's 13F filing for Q4 2023, filed 5 Feb 2024.